Clinical Research Directory
Browse clinical research sites, groups, and studies.
Gastric Emptying With Metoclopramide in GLP-1 Agonist Patients Undergoing Elective Surgery
Sponsor: Mater Misericordiae University Hospital
Summary
This is a multicentre, investigator-blinded, randomised controlled trial evaluating whether the use of oral metoclopramide before surgery can reduce the amount of residual gastric content in patients who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. These medications are known to slow down gastric emptying, which may increase the risk of pulmonary aspiration during anaesthesia. Patients will be randomly assigned to either receive metoclopramide 24 hours before surgery or continue with standard care. The primary outcome will be the presence or absence of residual gastric content on ultrasound before surgery. Secondary outcomes include nausea, vomiting, constipation, and any adverse effects of the medication.
Official title: Preoperative Metoclopramide to Enhance Gastric Emptying in Patients on Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Randomised Controlled Trial With Ultrasound Assessment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-08
Completion Date
2026-06
Last Updated
2025-08-06
Healthy Volunteers
No
Conditions
Interventions
Metoclopramide
Oral metoclopramide 10 mg, administered as three doses the day before surgery and one dose on the morning of surgery (total four doses over 24 hours). Used to enhance gastric emptying in patients taking GLP-1 receptor agonists.
Locations (2)
National Orthopaedic Hospital Cappagh
Dublin, Dublin 5, Ireland
Rotunda Hospital
Dublin, Ireland